{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:26:37Z","timestamp":1787837197685,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jns.2024.123017","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T23:43:27Z","timestamp":1713311007000},"page":"123017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Ten-year fracture risk in Japanese patients with myasthenia gravis: A comprehensive assessment using the fracture risk assessment tool"],"prefix":"10.1016","volume":"460","author":[{"given":"Shingo","family":"Konno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123017_bb0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123017_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J. Med. Life"},{"key":"10.1016\/j.jns.2024.123017_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274161","article-title":"Taskforce of validation of evidence-based diagnosis and guidelines, and impact on quality of life (QOL) in patients with neuroimmunological diseases, two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2024.123017_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","article-title":"Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey","volume":"305","author":"Murai","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2024.123017_bb0025","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jns.2024.123017_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clineuro.2003.12.001","article-title":"Bone density in myasthenia gravis patients receiving long-term prednisolone therapy","volume":"106","author":"Wakata","year":"2004","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2024.123017_bb0035","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00198-021-06101-3","article-title":"The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis","volume":"33","author":"Safipour","year":"2022","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jns.2024.123017_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126579","article-title":"Association between glucocorticoid-induced osteoporosis and myasthenia gravis: a cross-sectional study","volume":"10","author":"Konno","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2024.123017_bb0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00774-020-01181-3","article-title":"Two-year changes of bone mineral density in steroid-treated myasthenia gravis","volume":"39","author":"Suzuki","year":"2021","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jns.2024.123017_bb0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00198-012-1970-5","article-title":"Fracture rate in patients with myasthenia gravis: the general practice research database","volume":"24","author":"Pouwels","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jns.2024.123017_bb0055","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123017_bb0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jns.2024.123017_bb0065","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","article-title":"Guidance for the adjustment of FRAX according to the dose of glucocorticoids","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jns.2024.123017_bb0070","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.jns.2024.123017_bb0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update","volume":"32","author":"Suzuki","year":"2014","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jns.2024.123017_bb0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","article-title":"A systematic review of intervention thresholds based on FRAX: a report prepared for the national osteoporosis guideline group and the international osteoporosis foundation","volume":"11","author":"Kanis","year":"2016","journal-title":"Arch.Osteoporos."},{"key":"10.1016\/j.jns.2024.123017_bb0085","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2796.2005.01467.x","article-title":"Fracture risk associated with systemic and topical corticosteroids","volume":"257","author":"Vestergaard","year":"2005","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jns.2024.123017_bb0090","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jbmr.1582","article-title":"Manitoba bone density program, does osteoporosis therapy invalidate FRAX for fracture prediction?","volume":"27","author":"Leslie","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jns.2024.123017_bb0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"National Osteoporosis Guideline Group (NOGG), UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.jns.2024.123017_bb0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jns.2024.123017_bb0105","first-page":"1272","article-title":"Clinical risk factors for fractures in multi-ethnic women with and without osteoporosis","volume":"24","author":"Vestergaard","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jns.2024.123017_bb0110","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00198-010-1464-2","article-title":"Construction of a FRAX\u00ae model for the assessment of fracture probability in Canada and implications for treatment","volume":"22","author":"Leslie","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jns.2024.123017_bb0115","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00198-009-0845-x","article-title":"BMD, clinical risk factors and their combination for hip fracture prevention","volume":"20","author":"Johansson","year":"2009","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jns.2024.123017_bb0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00774-004-0596-x","article-title":"Subcommittee to Study Diagnostic Criteria for Glucocorticoid-Induced Osteoporosis. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004)","volume":"23","author":"Nawata","year":"2005","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jns.2024.123017_bb0125","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jns.2024.123017_bb0130","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheum."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T23:46:50Z","timestamp":1716335210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24001527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":26,"alternative-id":["S0022510X24001527"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123017","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ten-year fracture risk in Japanese patients with myasthenia gravis: A comprehensive assessment using the fracture risk assessment tool","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123017"}}